23.62 +0.31 (1.33%)
After hours: 6:51PM EDT
|Bid||23.26 x 100|
|Ask||23.70 x 2000|
|Day's Range||23.30 - 24.16|
|52 Week Range||18.03 - 32.50|
|PE Ratio (TTM)||47.28|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Stocks are under fresh pressure after new Federal Reserve chairman Jerome Powell sounded a hawkish note in his first appearance before Congress this week. The odds of four quarter-point rate hikes is now rising fast, pressuring long-term Treasury yields higher, bringing back the headwind that pushed stocks into a correction earlier this month.
Exelixis and Clovis shares diverged Tuesday after each reported lackluster sales of their biggest cancer drugs in the fourth quarter.
Exelixis' (EXEL) fourth-quarter results were positive wherein sales beat estimates on the back of Cabometyx growth while earnings met estimates.
Perrigo (PRGO) to reschedule fourth-quarter 2017 and full-year earnings results. However, the company releases preliminary unaudited numbers for the full year.
On a per-share basis, the South San Francisco, California-based company said it had net income of 12 cents. The results matched Wall Street expectations. The average estimate of eight analysts surveyed ...
Exelixis reported 12 cents earnings per share on $120.1 million in sales for the fourth quarter.
Exelixis (NASDAQ: EXEL ) will be releasing its next round of earnings Monday. For all of the relevant information, here is your guide for today's Q4 earnings announcement. Earnings and Revenue Wall Street ...
Exelixis Inc (NASDAQ:EXEL) is trading with a trailing P/E of 57.2x, which is higher than the industry average of 28.1x. While EXEL might seem like a stock to avoid orRead More...
Achillion Pharmaceuticals' (ACHN) fourth-quarter loss wider than estimates. The company is focusing on operational restructuring to save costs.
Corcept (CORT) reports in-line results for the fourth quarter of 2017 and also announces top-line interim phase II data for its pipeline candidate relacorilant.
Exelixis (EXEL) is likely to beat on earnings in the fourth quarter (results due on Feb 26) driven by growth in Cabometyx sales.
Novartis (NVS) announces positive results from the phase III study on multi-blockbuster drug Cosentyx for the treatment of moderate-to-severe scalp psoriasis.
AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.
Celgene (CELG) is looking to expand dermatology drug Otezla's label and reported positive data from a late-stage study in patients with active Beh??et???s Disease.
Acorda (ACOR) misses on earnings in Q4 but beats on revenue estimates. The company's key drug Ampyra witnesses an increase in sales both year over year and sequentially.
Roche (RHHBY) announces that it will acquire Flatiron Health to accelerate development and delivery of breakthrough drugs for cancer patients.